Table 3.
Patient-Years (%) of Warfarin by Indication and BRI
| Indication | Patient-years | BRI | ||
|---|---|---|---|---|
| Low | Intermediate | High | ||
| A. fib. | 556 | 32 (5.8) | 459 (82.5) | 65 (11.7) |
| Valve | 180 | 24 (13.3) | 131 (72.8) | 25 (13.9) |
| VTE | 203 | 53 (26.1) | 139 (68.5) | 11 (5.4) |
| CVA/TIA | 102 | 1 (1) | 57 (55.9) | 44 (43.1) |
| Hypercoagulable | 17 | 6 (35.3) | 9 (52.9) | 2 (11.8) |
| CMP | 50 | 5 (10) | 42 (84) | 3 (6) |
| MI | 20 | 0 | 20 (100) | 0 |
| PVD | 8 | 0 | 6 (75) | 2 (25) |
| Other | 172 | 11 (6.4) | 134 (77.9) | 27 (15.7) |
| Total | 1,308 | 132 (10.1) | 997 (76.2) | 179 (13.7) |
BRI, outpatient bleeding risk index; A. fib., atrial fibrillation; valve, heart valve replacement; VTE, venous thromboembolism; CVA/TIA, cerebrovascular accident/transient ischemic attack; hypercoagulable, hypercoagulable state (e.g., antiphospholipid antibody syndrome); CMP, cardiomyopathy; MI, myocardial infarction; PVD, peripheral vascular disease; Other, patients with multiple indications for warfarin (e.g., MI/CMP)